Viewing Study NCT02320032


Ignite Creation Date: 2025-12-24 @ 9:44 PM
Ignite Modification Date: 2025-12-31 @ 7:47 AM
Study NCT ID: NCT02320032
Status: COMPLETED
Last Update Posted: 2018-08-29
First Post: 2014-12-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
Sponsor: Alkermes, Inc.
Organization:

Study Overview

Official Title: A Phase 1, Randomized, Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
Status: COMPLETED
Status Verified Date: 2018-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of various doses and dosing intervals of aripiprazole lauroxil.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: